FIELD: pharmacy. SUBSTANCE: composition has at least one ligand showing a selective activity to RXRs,-receptors and at least one the second ligand showing a selective activity to RAR-α,-receptors in pharmaceutically acceptable carrier. Composition is used as a modulating agent for proliferation and/or differentiation of cells HL-60, in part, for systemic treatment of patients with acute promyelocytic leukemia. Composition can be used at low doses without tolerance and adverse effects. EFFECT: enhanced effectiveness of composition. 7 cl, 4 dwg, 2 ex
Authors
Dates
1998-10-20—Published
1995-07-26—Filed